Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2019 | The limitations of CAR-T currently: overcoming resistance

Loretta Nastoupil • 2 Apr 2019
BSH 2019
B-Cell Lymphoma Diffuse Large B-Cell Lymphoma General Lymphoma Non-Hodgkin Lymphoma CAR-T

Loretta Nastoupil, MD, MD Anderson Cancer Center, Houston, TX, discusses the limitations of CAR-T currently, focusing on resistance and explaining some of the approaches that are aiming to overcome this. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Loretta Nastoupil

1:10
NHL: What's hot at ASH 2023?
Loretta Nastoupil • 8 Dec 2023
2:20
Tazemetostat + lenalidomide & rituximab vs. lenalidomide & rituximab in patients with R/R FL
Loretta Nastoupil • 8 Dec 2023
1:48
TRANSCEND FL: liso-cel as 2L therapy in patients with high-risk R/R follicular lymphoma
Loretta Nastoupil • 8 Dec 2023
1:51
Optimizing immunotherapy for 3L or later R/R follicular lymphoma: liso-cel versus mosunetuzumab
Loretta Nastoupil • 8 Dec 2023

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals